Radiation detection, protection and dirty-bomb preparedness experts.
Loading organisations…
Clear filters
7 organisations in Radiological
Sort Best match · Name
Enzychem is a Korean drug developer whose EC-18 is an investigational countermeasure for acute radiation syndrome. It has FDA orphan drug designation and a material transfer agreement with the Armed Forces Radiobiology Research Institute.
Cellphire develops freeze-dried platelet products funded for radiation-related injury. CBRNE-relevant work is a notable product line according to its website. It is headquartered in Rockville, MD, United States.
Partner Therapeutics markets a drug approved for hematopoietic acute radiation syndrome. CBRNE-relevant work is a notable product line according to its website. It is headquartered in Lexington, MA, United States.
Pluri develops cell therapy candidates for acute radiation syndrome. CBRNE-relevant work is a notable product line according to its website. It is headquartered in Haifa, Israel.
Synedgen develops therapeutics including one for acute radiation syndrome. CBRNE-relevant work is a notable product line according to its website. It is headquartered in Claremont, CA, United States.
Amgen's Nplate is FDA-approved for hematopoietic acute radiation syndrome, and BARDA has bought more doses and funded an administration kit for it.
Global Resonance Technologies LLC offers products or services in these areas, according to its website: radiation detection & dosimetry, radiological countermeasures. CBRNE-relevant work is a minor part of its offering according to its website.